Russell Investments Group’s Cymabay Therapeutics CBAY Stock Holding History

Russell Investments Group’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-111,550	Closed	-$2.63M	–	3389
2023 Q4	$2.63M	Buy	111,550 +107,451	+2,621%	+$1.91M	﹤0.01%	1464
2023 Q3	$61.1K	Buy	+4,099	New	+$54.3K	﹤0.01%	2719
2021 Q1	–	Sell	-40,318	Closed	-$230K	–	3209
2020 Q4	$230K	Buy	40,318 +33,012	+452%	+$250K	﹤0.01%	2722
2020 Q3	$52K	Hold	7,306	–	–	﹤0.01%	3072
2020 Q2	$25K	Buy	+7,306	New	+$21.1K	﹤0.01%	3040
2020 Q1	–	Sell	-25,000	Closed	-$49K	–	3171
2019 Q4	$49K	Buy	+25,000	New	+$93.9K	﹤0.01%	2995

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Russell Investments Group's CBAY Position: Q1 2024 in Review

Russell Investments Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 111,550 shares — an estimated $2.63M sold.

Russell Investments Group first reported a position in CBAY in Q4 2019 and held it in 6 quarters. The position peaked at $2.63M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Russell Investments Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Russell Investments Group sold 111,550 Cymabay Therapeutics shares in Q1 2024, an estimated $2.63M.
Russell Investments Group first reported a position in Cymabay Therapeutics in Q4 2019 and held it in 6 quarters.
Russell Investments Group's Cymabay Therapeutics position peaked at $2.63M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Russell Investments Group's 13F filing for Q1 2024, filed 8 May 2024.